BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35066694)

  • 21. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening.
    Hueso T; Ekpe K; Mayeur C; Gatse A; Joncquel-Chevallier Curt M; Gricourt G; Rodriguez C; Burdet C; Ulmann G; Neut C; Amini SE; Lepage P; Raynard B; Willekens C; Micol JB; De Botton S; Yakoub-Agha I; Gottrand F; Desseyn JL; Thomas M; Woerther PL; Seguy D
    Gut Microbes; 2020 Nov; 12(1):1800897. PubMed ID: 32893715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
    Nishi R; Shigemi H; Negoro E; Okura M; Hosono N; Yamauchi T
    BMC Cancer; 2020 Oct; 20(1):984. PubMed ID: 33046037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis.
    Zhang H; Liu L; Chen L; Liu H; Ren S; Tao Y
    Mol Oncol; 2021 Apr; 15(4):1203-1216. PubMed ID: 33638615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
    Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
    Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
    Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitocurcumin utilizes oxidative stress to upregulate JNK/p38 signaling and overcomes Cytarabine resistance in acute myeloid leukemia.
    Gaur T; Ali A; Sharma D; Gupta SK; Gota V; Bagal B; Platzbeckar U; Mishra R; Dutt A; Khattry N; Mills K; Hassan MI; Sandur S; Hasan SK
    Cell Signal; 2024 Feb; 114():111004. PubMed ID: 38048856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-6 promotes chemoresistance via upregulating CD36 mediated fatty acids uptake in acute myeloid leukemia.
    Zhang Y; Guo H; Zhang Z; Lu W; Zhu J; Shi J
    Exp Cell Res; 2022 Jun; 415(1):113112. PubMed ID: 35346671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.
    Gandhi V; Estey E; Keating MJ; Plunkett W
    J Clin Oncol; 1993 Jan; 11(1):116-24. PubMed ID: 8418222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.
    Zhao W; Wei L; Tan D; Su G; Zheng Y; He C; Mao ZJ; Singleton TP; Yin B
    PLoS One; 2014; 9(10):e109198. PubMed ID: 25314317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines.
    Lishner M; Bar-Sef A; Elis A; Fabian I
    J Investig Med; 2001 Jul; 49(4):319-24. PubMed ID: 11478407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
    Ying M; Zhou X; Zhong L; Lin N; Jing H; Luo P; Yang X; Song H; Yang B; He Q
    Mol Cancer Ther; 2013 Feb; 12(2):195-206. PubMed ID: 23243061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.
    Wunderlich M; Mizukawa B; Chou FS; Sexton C; Shrestha M; Saunthararajah Y; Mulloy JC
    Blood; 2013 Mar; 121(12):e90-7. PubMed ID: 23349390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergism of Curcumin and Cytarabine in the Down Regulation of Multi-Drug Resistance Genes in Acute Myeloid Leukemia.
    Shah K; Mirza S; Desai U; Jain N; Rawal R
    Anticancer Agents Med Chem; 2016; 16(1):128-35. PubMed ID: 26278546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.
    Nishi R; Yamauchi T; Negoro E; Takemura H; Ueda T
    Cancer Sci; 2013 Apr; 104(4):502-7. PubMed ID: 23320492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
    Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
    Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.